Abstract

Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with biologics. This study aimed to investigate the budget impact of adopting biosimilar infliximab in five European countries, considering that the budget impact includes the adoption of biosimilar infliximab and the availability of biologic alternatives such as vedolizumab, biosimilar etanercept, biosimilar rituximab, and other relevant factors.Methods: An existing budget impact model was adapted to forecast the budget impact in the UK, Germany, France, Spain, and Italy. Epidemiological parameters were derived from published literature reviewed in July 2015. Current market shares of biologics were derived from Therapy Watch (2012/2013 data). Respondents in a Delphi panel, conducted in 2015 and consisting of several leading rheumatologists and gastroenterologists from different nationalities, were asked to forecast uptake of biosimilar infliximab and estimate the proportion of patients eligible for a particular type of biological treatment, including biosimilar infliximab. Scenario analyses assessed the influence of various factors, including price reductions, on the budget.Results: Uptake of biosimilar infliximab was particularly expected for naïve patients; switching patients that already received other biologics was not expected much. Market shares after 5 years of biosimilar infliximab were ~2% in rheumatology in all five countries and in gastroenterology ranged from 4% in France to over 30% in Italy. Except for France, budgets were expected to decrease for rheumatologic diseases. For gastroenterology, budgets were expected to decrease in Spain and Italy. Budgets were expected to increase substantially in the UK and Germany, due to the introduction of vedolizumab in the studied period. In France, budget was expected to slightly increase for ankylosing spondylitis, Crohn's Disease, and ulcerative collitis. Savings in budget were expected in all countries, for all diseases, when larger price discounts on biosimilar infliximab were used.Discussion and Conclusion: This study has shown that only when price reductions are large enough (i.e., 50% or more), physicians indicated that they will prescribe biosimilars. Policy makers should ensure substantial price reductions and stimulate physicians to use biosimilar products, to obtain savings in healthcare budgets.

Highlights

  • Introducing biosimilar infliximab for the treatment in rheumatology and inflammatory bowel disease (Crohn’s disease and ulcerative colitis) may reduce treatment costs associated with biologics

  • This study assessed the budget impact of adopting biosimilar infliximab for rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn’s disease (CD), and ulcerative colitis (UC) in the EU5, using specialist assumptions derived from a Delphi survey performed in 2015

  • To the best of the authors’ knowledge, this is the first study that calculates the budget impact taking into account the adoption of biosimilar infliximab and the availability of biologic alternatives such as vedolizumab, biosimilar etanercept, and biosimilar rituximab

Read more

Summary

Introduction

Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn’s disease and ulcerative colitis) may reduce treatment costs associated with biologics. Biological drugs acting as anti-tumor necrosis factors (TNF), inhibitors of the T- and B-cell costimulation, and inhibitors of the interleukin (IL)-6 and the IL-1 have been shown to successfully reach treatment targets (e.g., remission, low disease activity) and improve patients’ quality of life for several gastrointestinal and rheumatic diseases in a number of clinical situations (Mathias et al, 2000; Dignass et al, 2010, 2012; Lichtiger et al, 2010; Braun et al, 2011; Smolen et al, 2014) Both knowledge and experience gained with these drugs have supported their acceptance by gastroenterologists and rheumatologists, and the drugs’ integration in the treatment algorithms of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC)—together named gastroenterological indications, rheumatoid arthritis (RA), and ankylosing spondylitis (AS)—together named rheumatological indications (Dignass et al, 2010, 2012; Braun et al, 2011; Smolen et al, 2014). In a cost study of IBD in the Dutch setting, the cost of anti-TNF drugs was estimated to account for 64 and 54% of the total healthcare costs of CD and UC, respectively (van der Valk et al, 2014)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.